Document Type : Original Article
Authors
Department of Chemistry, College of Science, University of Thi-Qar, Thi-Qar, 64001, Iraq.
Abstract
The cardiovascular system benefits from dapagliflozin, a member of the class of hypoglycemia medications known as SGLT-2 inhibitors. The purpose of the current research is to compare the levels of NT-Pro BNP, creatinine, urea, K, and Na in patients to those in healthy individuals (controls). There were 150 participants in the research: 100 patients with Type 2 Diabetes Mellitus (T2DM) and heart failure (HF), and 50 controls. Based on age, the patients are split into two groups (40-70). Whereas the second group (B) just received Lasix, the first group (A) received both Lasix and dapagliflozin. Compared with the control group, group B's serum concentration of NT-Pro BNP, creatinine, and urea increased significantly (p ≤ 0.050). Compared to controls, group B had a significant drop in serum Na concentration (p ≤ 0.05). Serum concentrations of NT-Pro BNP, Creatinine, Urea, and Na in group B are not significantly different from those in group A at the time of admission. When compared to group A, group B exhibits significant differences in serum K concentration. Serum concentrations of NT-ProBNP, Creatinine, Urea, Potassium, and Sodium do not differ significantly between groups B and A at 7 days, according to the data. Additionally, in comparison with the day of baseline, the concentration of serum NT-pro-BNP in patients in groups B and A was significantly lower on the seventh day of baseline. Dapagliflozin works well to lower NT-Pro BNP levels and alleviate the symptoms of HF. It improves cardiac function, quality of life, and reduces fluid retention.
Keywords
)
View on SCiNiTO